MENUNews Archive
Date: 06/30/2019
Black men are more likely to be diagnosed with prostate cancer and nearly 2.5 times more likely to die of the disease compared to non-Hispanic white men. The question is why. Are black men more likely to carry genes that drive deadlier forms of the disease? What societal disparities might be affecting outcomes?
Date: 06/19/2019
Cancer is not simply masses of cells but structured organs with multiple cell types that communicate with each other and interact with the body -- much like your lungs or liver.
Date: 06/07/2019
The update on the KEYNOTE-189 trial provides nearly two years data on use of the immunotherapy drug pembrolizumab in combination with platinum-based chemotherapy as a first-line treatment for metastatic non-small cell lung cancer.
Date: 06/05/2019
A technique that illuminates blood flow during surgery predicted which head and neck cancer patients were likely to have issues with wound healing.
Date: 05/23/2019
A prototype wearable device, tested in animal models, can continuously collect live cancer cells directly from a patient’s blood.
Date: 05/23/2019
Selected jointly by the Rogel Cancer Center and the Medical School’s Office of Admissions, the students have all indicated interest in establishing a career in cancer research.
Date: 05/23/2019
A potential new immune-based therapy to treat precancers in the cervix completely eliminated both the lesion and the underlying HPV infection in a third of women enrolled in a clinical trial. The shot, a therapeutic vaccine, injects a specific protein that triggers an immune system response to attack high-risk HPV types that cause nearly all cervical cancer precursors, known as cervical intraepithelial neoplasia, or CIN.
Date: 05/22/2019
Researchers at the University of Michigan Rogel Cancer Center have developed a new method for lifting the genetic fingerprints of tiny fragments of RNA found in blood plasma that are invisible to traditional methods of RNA sequencing.
Date: 05/14/2019
Now, in mouse models and prostate cancer cell lines, U-M researchers have demonstrated the preliminary effectiveness of a new set of compounds that offer a potential advance in the treatment of metastatic castration-resistant prostate cancer -- one that appears to avoid many of the usual mechanisms of treatment resistance.
Date: 05/10/2019
Fourteen University of Michigan Rogel Cancer Center researchers will have the opportunity and freedom to pursue new directions in their work. These faculty members comprise the inaugural class of Rogel Scholars, a select designation with research support funded as part of a $150 million commitment from Richard and Susan Rogel.